Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma

New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification of an appropriate dose regimen fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, XS, Yan, X, Puchalski, T, Lonial, S, Lokhorst, HM, Voorhees, PM, Plesner, T, Liu, K, Khan, I, Jansson, R, Ahmadi, T, Ruixo, JJ Perez, Zhou, H, Clemens, PL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Development
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485722/
https://www.ncbi.nlm.nih.gov/pubmed/27859027
http://dx.doi.org/10.1002/cpt.577
_version_ 1783246126555594752
author Xu, XS
Yan, X
Puchalski, T
Lonial, S
Lokhorst, HM
Voorhees, PM
Plesner, T
Liu, K
Khan, I
Jansson, R
Ahmadi, T
Ruixo, JJ Perez
Zhou, H
Clemens, PL
author_facet Xu, XS
Yan, X
Puchalski, T
Lonial, S
Lokhorst, HM
Voorhees, PM
Plesner, T
Liu, K
Khan, I
Jansson, R
Ahmadi, T
Ruixo, JJ Perez
Zhou, H
Clemens, PL
author_sort Xu, XS
collection PubMed
description New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification of an appropriate dose regimen for daratumumab is challenging due to its target‐mediated drug disposition, leading to time‐ and concentration‐dependent pharmacokinetics. We describe a thorough evaluation of the recommended dose regimen for daratumumab in patients with relapsed or refractory MM.
format Online
Article
Text
id pubmed-5485722
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-54857222017-07-03 Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma Xu, XS Yan, X Puchalski, T Lonial, S Lokhorst, HM Voorhees, PM Plesner, T Liu, K Khan, I Jansson, R Ahmadi, T Ruixo, JJ Perez Zhou, H Clemens, PL Clin Pharmacol Ther Development New therapeutic strategies are urgently needed to improve clinical outcomes in patients with multiple myeloma (MM). Daratumumab is a first‐in‐class, CD38 human immunoglobulin G1κ monoclonal antibody approved for treatment of relapsed or refractory MM. Identification of an appropriate dose regimen for daratumumab is challenging due to its target‐mediated drug disposition, leading to time‐ and concentration‐dependent pharmacokinetics. We describe a thorough evaluation of the recommended dose regimen for daratumumab in patients with relapsed or refractory MM. John Wiley and Sons Inc. 2017-02-13 2017-06 /pmc/articles/PMC5485722/ /pubmed/27859027 http://dx.doi.org/10.1002/cpt.577 Text en © 2017 The Authors Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Development
Xu, XS
Yan, X
Puchalski, T
Lonial, S
Lokhorst, HM
Voorhees, PM
Plesner, T
Liu, K
Khan, I
Jansson, R
Ahmadi, T
Ruixo, JJ Perez
Zhou, H
Clemens, PL
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
title Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
title_full Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
title_fullStr Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
title_full_unstemmed Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
title_short Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
title_sort clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma
topic Development
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485722/
https://www.ncbi.nlm.nih.gov/pubmed/27859027
http://dx.doi.org/10.1002/cpt.577
work_keys_str_mv AT xuxs clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT yanx clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT puchalskit clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT lonials clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT lokhorsthm clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT voorheespm clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT plesnert clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT liuk clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT khani clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT janssonr clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT ahmadit clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT ruixojjperez clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT zhouh clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma
AT clemenspl clinicalimplicationsofcomplexpharmacokineticsfordaratumumabdoseregimeninpatientswithrelapsedrefractorymultiplemyeloma

Ejemplares similares